Where the 156 tracked surgical-AI companies land. Bars are proportional to company count.
INC
10 of 156
6.4%
Incumbent / corporate platform: AI functions as core platform capability for an established franchise; AI-specific revenue is not the aim
PROC
5 of 156
3.2%
Procedure-economics path: viability rides on owning a billable procedure (CPT/DRG plus consumables); AI is embedded in the procedure
IND
9 of 156
5.8%
Plausible standalone: a credible independent revenue path, typically ROI-based sales (OR operations, revenue cycle), B2B tooling, or payment-aligned services
ACQ
35 of 156
22.4%
Feature / integration path: real capability whose value is most naturally realized through partnership, licensing, or acquisition by a larger platform
CN
25 of 156
16.0%
China-shaped economics: NMPA regulation, NHSA pricing, and volume-based procurement set the economics; domestic volume plus export is the model
NICHE
23 of 156
14.7%
Sustainable niche / regional: real businesses at focused scale (Japan add-ons, NHS, defense, cash-pay, services, education)
RISK
39 of 156
25.0%
Earlier-stage / watch list: limited disclosed funding, an unresolved payment path, or limited recent public activity; outcomes depend on next financing or partnership
DONE
10 of 156
6.4%
Outcome already resolved: acquired, merged into a larger owner, operating as a corporate unit, repositioned, or inactive